Timo Nuijens
Research Subjects
Timo Nuijens has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Ana Toplak
EnzyPep B.V., Brightlands Campus Urmonderbaan 22, 6167 RD Geleen, The Netherlands
8 shared publications- Marcel Schmidt
Van ‘t Hoff Institute for Molecular Sciences (HIMS) Science Park 904 1098 XH Amsterdam The Netherlands
8 shared publications Jan H. van Maarseveen
Van 't Hoff Institute for Molecular Sciences (HIMS), University of Amsterdam, Science Park 904, 1098 XH, Amsterdam, The Netherlands
5 shared publications- Dirk T. S. Rijkers
Medicinal Chemistry and Chemical Biology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
3 shared publications Hein J. Wijma
Biotransformation and Biocatalysis, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands
3 shared publicationsMarcel Schmidt
EnzyPep B.V., Brightlands Campus Urmonderbaan 22, 6167 RD Geleen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 19, 1277-1287
From thiol-subtilisin to omniligase: Design and structure of a broadly applicable peptide ligase
Omniligase-1 is a broadly applicable enzyme for peptide bond formation between an activated acyl donor peptide and a non-protected acyl acceptor peptide. The enzyme is derived from an earlier subtilisin variant called peptiligase by several rounds of protein engineering aimed at increasing synthetic yields and substrate range. To examine the contribution of individual mutations on S/H ratio and substrate scope in peptide synthesis, we selected peptiligase variant M222P/L217H as a starting enzyme and introduced successive mutations. Mutation A225N in the S1′ pocket and F189W of the S2′ pocket increased the synthesis to hydrolysis (S/H) ratio and overall coupling efficiency, whereas the I107V mutation was added to S4 pocket to increase the reaction rate. The final omniligase variants appeared to have a very broad substrate range, coupling more than 250 peptides in a 400-member library of acyl acceptors, as indicated by a high-throughput FRET assay. Crystal structures and computational modelling could rationalize the exceptional properties of omniligase-1 in peptide synthesis
- 1 January 2021
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 19, 1277-1287
Open AccessFrom thiol-subtilisin to omniligase: Design and structure of a broadly applicable peptide ligase
Omniligase-1 is a broadly applicable enzyme for peptide bond formation between an activated acyl donor peptide and a non-protected acyl acceptor peptide. The enzyme is derived from an earlier subtilisin variant called peptiligase by several rounds of protein engineering aimed at increasing synthetic yields and substrate range. To examine the contribution of individual mutations on S/H ratio and substrate scope in peptide synthesis, we selected peptiligase variant M222P/L217H as a starting enzyme and introduced successive mutations. Mutation A225N in the S1′ pocket and F189W of the S2′ pocket increased the synthesis to hydrolysis (S/H) ratio and overall coupling efficiency, whereas the I107V mutation was added to S4 pocket to increase the reaction rate. The final omniligase variants appeared to have a very broad substrate range, coupling more than 250 peptides in a 400-member library of acyl acceptors, as indicated by a high-throughput FRET assay. Crystal structures and computational modelling could rationalize the exceptional properties of omniligase-1 in peptide synthesis
- 7 November 2019
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 21 (23) , 6451-6467
Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
Using a large scale biocatalytic manufacture of the antidiabetic exenatide as an example, we report that chemo-enzymatic peptide synthesis (CEPS) constitutes an efficient method for sustainable manufacturing of therapeutic peptides. The H-22-39-NH2 and H-1-21-O-Cam-L-NH2 exenatide fragments requisite for the enzymatic ligations were synthesized by solid-phase peptide synthesis (SPPS) methods and in ligations of these fragments catalyzed by omniligase-1, a broad specificity ligase engineered from subtilisin BPN’, we found that at pH 9.1/37 °C a substantial formation of deamidation impurities occurs. Consequently, a more robust ligation protocol (pH 7.5, rt, 10% MeCN as co-solvent) was developed and used in efficient scale-up ligations of the two fragments both as crude peptides as well as in their purified forms. Further, the aromatic 4-hydroxymethylbenzoic acid (HMBA) was evaluated as a more robust alternative for the carboxamidomethyl (O-Cam linker), which exhibited limited stability during some steps of the elevated temperature (ET) SPPS of the H-1-21-O-Cam-L-NH2 fragment. An SPPS process to obtain H-1-21-HMBA-K fragment in good yield and purity was developed and this peptide was used with the H-22-39-NH2 fragment in a large scale omniligase-1 catalyzed ligation affording 53 g of crude exenatide with excellent yield and high turnover numbers (TON). The crude product was purified to obtain exenatide API, demonstrating that CEPS can be used for large scale manufacturing of therapeutic peptides in economically as well as environmentally sustainable manner. Cost of manufacturing, complete E factor (cEF) and Carbon Intensity (CI) were determined for all process routes herein vs. a conventional and a lab scale CEPS benchmark processes. This revealed that the CEPS exenatide processes which employed the H-1-21-HMBA-K fragment were not only successfully scaled but also improved in terms of economy as well as environmental footprint compared to both benchmark process routes.
- 7 November 2019
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 21 (23) , 6451-6467
Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
Using a large scale biocatalytic manufacture of the antidiabetic exenatide as an example, we report that chemo-enzymatic peptide synthesis (CEPS) constitutes an efficient method for sustainable manufacturing of therapeutic peptides. The H-22-39-NH2 and H-1-21-O-Cam-L-NH2 exenatide fragments requisite for the enzymatic ligations were synthesized by solid-phase peptide synthesis (SPPS) methods and in ligations of these fragments catalyzed by omniligase-1, a broad specificity ligase engineered from subtilisin BPN’, we found that at pH 9.1/37 °C a substantial formation of deamidation impurities occurs. Consequently, a more robust ligation protocol (pH 7.5, rt, 10% MeCN as co-solvent) was developed and used in efficient scale-up ligations of the two fragments both as crude peptides as well as in their purified forms. Further, the aromatic 4-hydroxymethylbenzoic acid (HMBA) was evaluated as a more robust alternative for the carboxamidomethyl (O-Cam linker), which exhibited limited stability during some steps of the elevated temperature (ET) SPPS of the H-1-21-O-Cam-L-NH2 fragment. An SPPS process to obtain H-1-21-HMBA-K fragment in good yield and purity was developed and this peptide was used with the H-22-39-NH2 fragment in a large scale omniligase-1 catalyzed ligation affording 53 g of crude exenatide with excellent yield and high turnover numbers (TON). The crude product was purified to obtain exenatide API, demonstrating that CEPS can be used for large scale manufacturing of therapeutic peptides in economically as well as environmentally sustainable manner. Cost of manufacturing, complete E factor (cEF) and Carbon Intensity (CI) were determined for all process routes herein vs. a conventional and a lab scale CEPS benchmark processes. This revealed that the CEPS exenatide processes which employed the H-1-21-HMBA-K fragment were not only successfully scaled but also improved in terms of economy as well as environmental footprint compared to both benchmark process routes.
- 4 June 2019
- Published by Springer Nature
- Vol. 2012, 43-61
Chemoenzymatic Synthesis of Linear- and Head-to-Tail Cyclic Peptides Using Omniligase-1
Omniligase-1-catalyzed ligation represents a powerful tool for the efficient intermolecular and intramolecular (head-to-tail cyclization) ligation of peptides. Reactions are irreversible and proceed with unprotected peptides (μM–mM concentration) in aqueous solution at slightly basic pH. Due to its high catalytic efficiency, only very low molar equivalents of omniligase-1 are required. In this chapter, a chemoenzymatic peptide synthesis (CEPS) approach for the assembly of medium-to-long-sized linear peptides as well as for efficient peptide head-to-tail cyclization is described. In particular, we provide protocols for the chemoenzymatic synthesis of the peptide therapeutic exenatide, a GLP-1 (glucagon-like peptide) analogue, and the macrocyclization and oxidative folding of the cyclotide MCoTI-II in a one-pot procedure.
- 4 June 2019
- Published by Springer Nature
- Vol. 2012, 43-61
Chemoenzymatic Synthesis of Linear- and Head-to-Tail Cyclic Peptides Using Omniligase-1
Omniligase-1-catalyzed ligation represents a powerful tool for the efficient intermolecular and intramolecular (head-to-tail cyclization) ligation of peptides. Reactions are irreversible and proceed with unprotected peptides (μM–mM concentration) in aqueous solution at slightly basic pH. Due to its high catalytic efficiency, only very low molar equivalents of omniligase-1 are required. In this chapter, a chemoenzymatic peptide synthesis (CEPS) approach for the assembly of medium-to-long-sized linear peptides as well as for efficient peptide head-to-tail cyclization is described. In particular, we provide protocols for the chemoenzymatic synthesis of the peptide therapeutic exenatide, a GLP-1 (glucagon-like peptide) analogue, and the macrocyclization and oxidative folding of the cyclotide MCoTI-II in a one-pot procedure.
- 8 February 2019
- Published by Wiley in ChemBioChem
- Vol. 20 (12) , 1524-1529
Efficient Enzymatic Cyclization of Disulfide‐Rich Peptides by Using Peptide Ligases
Disulfide‐rich macrocyclic peptides—cyclotides, for example—represent a promising class of molecules with potential therapeutic use. Despite their potential their efficient synthesis at large scale still represents a major challenge. Here we report new chemoenzymatic strategies using peptide ligase variants—inter alia, omniligase‐1—for the efficient and scalable one‐pot cyclization and folding of the native cyclotides MCoTI‐II, kalata B1 and variants thereof, as well as of the θ‐defensin RTD‐1. The synthesis of the kB1 variant T20K was successfully demonstrated at multi‐gram scale. The existence of several ligation sites for each macrocycle makes this approach highly flexible and facilitates both the larger‐scale manufacture and the engineering of bioactive, grafted cyclotide variants, therefore clearly offering a valuable and powerful extension of the existing toolbox of enzymes for peptide head‐to‐tail cyclization.
- 8 February 2019
- Published by Wiley in ChemBioChem
- Vol. 20 (12) , 1524-1529
Efficient Enzymatic Cyclization of Disulfide‐Rich Peptides by Using Peptide Ligases
Disulfide‐rich macrocyclic peptides—cyclotides, for example—represent a promising class of molecules with potential therapeutic use. Despite their potential their efficient synthesis at large scale still represents a major challenge. Here we report new chemoenzymatic strategies using peptide ligase variants—inter alia, omniligase‐1—for the efficient and scalable one‐pot cyclization and folding of the native cyclotides MCoTI‐II, kalata B1 and variants thereof, as well as of the θ‐defensin RTD‐1. The synthesis of the kB1 variant T20K was successfully demonstrated at multi‐gram scale. The existence of several ligation sites for each macrocycle makes this approach highly flexible and facilitates both the larger‐scale manufacture and the engineering of bioactive, grafted cyclotide variants, therefore clearly offering a valuable and powerful extension of the existing toolbox of enzymes for peptide head‐to‐tail cyclization.
- Open Access
- 11 September 2018
- Published by Wiley in ChemBioChem
- Vol. 19 (18) , 1899
Cover Feature: A One‐Pot “Triple‐C” Multicyclization Methodology for the Synthesis of Highly Constrained Isomerically Pure Tetracyclic Peptides (ChemBioChem 18/2018)
- 11 September 2018
- Published by Wiley in ChemBioChem
- Vol. 19 (18) , 1899
Open AccessCover Feature: A One‐Pot “Triple‐C” Multicyclization Methodology for the Synthesis of Highly Constrained Isomerically Pure Tetracyclic Peptides (ChemBioChem 18/2018)
- 26 June 2018
- Published by Wiley in ChemBioChem
- Vol. 19 (18) , 1934-1938
A One‐Pot “Triple‐C” Multicyclization Methodology for the Synthesis of Highly Constrained Isomerically Pure Tetracyclic Peptides
A broadly applicable one‐pot methodology for the facile transformation of linear peptides into tetracyclic peptides through a chemoenzymatic peptide synthesis/chemical ligation of peptides onto scaffolds/copper(I)‐catalyzed reaction (CEPS/CLIPS/CuAAC; “triple‐C”) locking methodology is reported. Linear peptides with varying lengths (≥14 amino acids), comprising two cysteines and two azidohomoalanines (Aha), were efficiently cyclized head‐to‐tail by using the peptiligase variant omniligase‐1 (CEPS). Subsequent ligation–cyclization with tetravalent (T41/2) scaffolds containing two bromomethyl groups (CLIPS) and two alkyne functionalities (CuAAC) yielded isomerically pure tetracyclic peptides. Sixteen different functional tetracycles, derived from bicyclic inhibitors against urokinase plasminogen activator (uPA) and coagulation factor XIIa (FXIIa), were successfully synthesized and their bioactivities evaluated. Two of these (FF‐T41/2) exhibited increased inhibitory activity against FXIIa, compared with a bicyclic control peptide. The corresponding hetero‐bifunctional variants (UF/FU‐T41/2), with a single copy of each inhibitory sequence, exhibited micromolar activities against both uPA and FXIIa; thus illustrating the potential of the “bifunctional tetracyclic peptide” inhibitor concept.
- 26 June 2018
- Published by Wiley in ChemBioChem
- Vol. 19 (18) , 1934-1938
A One‐Pot “Triple‐C” Multicyclization Methodology for the Synthesis of Highly Constrained Isomerically Pure Tetracyclic Peptides
A broadly applicable one‐pot methodology for the facile transformation of linear peptides into tetracyclic peptides through a chemoenzymatic peptide synthesis/chemical ligation of peptides onto scaffolds/copper(I)‐catalyzed reaction (CEPS/CLIPS/CuAAC; “triple‐C”) locking methodology is reported. Linear peptides with varying lengths (≥14 amino acids), comprising two cysteines and two azidohomoalanines (Aha), were efficiently cyclized head‐to‐tail by using the peptiligase variant omniligase‐1 (CEPS). Subsequent ligation–cyclization with tetravalent (T41/2) scaffolds containing two bromomethyl groups (CLIPS) and two alkyne functionalities (CuAAC) yielded isomerically pure tetracyclic peptides. Sixteen different functional tetracycles, derived from bicyclic inhibitors against urokinase plasminogen activator (uPA) and coagulation factor XIIa (FXIIa), were successfully synthesized and their bioactivities evaluated. Two of these (FF‐T41/2) exhibited increased inhibitory activity against FXIIa, compared with a bicyclic control peptide. The corresponding hetero‐bifunctional variants (UF/FU‐T41/2), with a single copy of each inhibitory sequence, exhibited micromolar activities against both uPA and FXIIa; thus illustrating the potential of the “bifunctional tetracyclic peptide” inhibitor concept.
- 4 January 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (4) , 609-618
Design of a substrate-tailored peptiligase variant for the efficient synthesis of thymosin-α1
A substrate-tailored peptide ligase for the chemo-enzymatic peptide synthesis (CEPS) of thymosin-α1.
- 4 January 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (4) , 609-618
Design of a substrate-tailored peptiligase variant for the efficient synthesis of thymosin-α1
A substrate-tailored peptide ligase for the chemo-enzymatic peptide synthesis (CEPS) of thymosin-α1.
- 1 December 2017
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 26, 11-16
Enzyme-catalyzed peptide cyclization
- 1 December 2017
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 26, 11-16
Enzyme-catalyzed peptide cyclization
- 1 June 2017
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 38, 1-7
Enzyme-mediated ligation technologies for peptides and proteins
- 1 June 2017
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 38, 1-7
Enzyme-mediated ligation technologies for peptides and proteins
- 18 May 2017
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 359 (12) , 2010
Cover Picture: Omniligase‐1: A Powerful Tool for Peptide Head‐to‐Tail Cyclization (Adv. Synth. Catal. 12/2017)
- 18 May 2017
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 359 (12) , 2010
Cover Picture: Omniligase‐1: A Powerful Tool for Peptide Head‐to‐Tail Cyclization (Adv. Synth. Catal. 12/2017)